FDA rejects cancer therapy positioned to rival Novartis treatment
The FDA has rejected a radiopharmaceutical therapy from ITM Isotope Technologies Munich that was positioned to compete with Novartis’ leading treatments in the space. The agency issued a complete response letter for ITM-11, also known as 177Lu-edotreotide, saying it cannot approve the new drug application in its current form, according to an Aug. 10 news […] The post FDA rejects cancer therapy positioned to rival Novartis treatment appeared first on Becker's Hospital Review | He...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.